Bruker announced on December 8, 2025, that Jack J. Phillips will join its Board of Directors effective January 1, 2026. The addition of the member aligns with Bruker’s expanding diagnostics strategy as the company extends its infectious disease diagnostics portfolio.
Phillips is a leader who has more than 30 years of diagnostic-related industry experience to his credit. From 2020 to 2025, he served as President & CEO of Accelerate Diagnostics. Under his leadership, the company advanced rapid AST solutions for hospitals battling multi-resistant infections and sepsis. Before that, he served as President & CEO of Roche Diagnostics North America from 2010 to 2020. During this period, he managed a broad diagnostics portfolio, including clinical chemistry, immunodiagnostics, molecular diagnostics, and point-of-care testing.
To add, between 1999 and 2010, Phillips served as Senior Vice President & General Manager for North America Ventana Medical Systems. During this time, he helped establish tissue and companion diagnostics as recognized tools of standard care.
Bruker Corporation’s Chairman, President, and CEO Frank H. Laukien said the board will strongly benefit from Phillips’s deep diagnostics expertise and strong market insight. He also said that Phillips’ experience will be instrumental in converting scientific innovations into real-world clinical applications while maintaining profitability.
Phillips said he views diagnostics as separate technologies but as a unified ecosystem that converts biological insight into meaningful clinical. He said he is eager to bring his knowledge and foresight to the board of Bruker.
In addition, Bruker is strengthening its leadership team by bringing Phillips on board. The company is also accelerating its efforts in diagnostics, infectious disease testing, and specialty diagnostic tools.
For more stories on executive leadership and business innovations, explore our CXO Insiders for the latest updates.
Source: Businesswire
